<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Respir Res</journal-id><journal-id journal-id-type="iso-abbrev">Respir. Res</journal-id><journal-title-group><journal-title>Respiratory Research</journal-title></journal-title-group><issn pub-type="ppub">1465-9921</issn><issn pub-type="epub">1465-993X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28826397</article-id><article-id pub-id-type="pmc">5563904</article-id><article-id pub-id-type="publisher-id">638</article-id><article-id pub-id-type="doi">10.1186/s12931-017-0638-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension&#x02122; Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Reisner</surname><given-names>Colin</given-names></name><address><email>creisner@pearltherapeutics.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fabbri</surname><given-names>Leonardo M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kerwin</surname><given-names>Edward M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fogarty</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Spangenthal</surname><given-names>Selwyn</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Rabe</surname><given-names>Klaus F.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ferguson</surname><given-names>Gary T.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Martinez</surname><given-names>Fernando J.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Donohue</surname><given-names>James F.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Darken</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>St. Rose</surname><given-names>Earl</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Orevillo</surname><given-names>Chad</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Strom</surname><given-names>Shannon</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Tracy</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Golden</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Dwivedi</surname><given-names>Sarvajna</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution/><institution>Pearl Therapeutics Inc., </institution></institution-wrap>280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960 USA </aff><aff id="Aff2"><label>2</label>Department of Medicine, University of Modena and Reggio Emilia, NOCSAE, Modena, Italy </aff><aff id="Aff3"><label>3</label>Clinical Research Institute of Southern Oregon, Medford, OR USA </aff><aff id="Aff4"><label>4</label>Spartanburg Medical Research, Spartanburg, NC USA </aff><aff id="Aff5"><label>5</label>American Health Research, Charlotte, NC USA </aff><aff id="Aff6"><label>6</label>Lungen Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany </aff><aff id="Aff7"><label>7</label>Department of Medicine, Christian-Albrechts University Kiel, Kiel, MI USA </aff><aff id="Aff8"><label>8</label>Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936877X</institution-id><institution-id institution-id-type="GRID">grid.5386.8</institution-id><institution/><institution>Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College; New York-Presbyterian Hospital/Weill Cornell MedicalCenter, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution>Department of Medicine, </institution><institution>University of North Carolina School of Medicine, </institution></institution-wrap>Chapel Hill, NC USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution/><institution>Pearl Therapeutics Inc., </institution></institution-wrap>Durham, NC USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution/><institution>Pearl Therapeutics Inc., </institution></institution-wrap>Redwood City, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>18</volume><elocation-id>158</elocation-id><history><date date-type="received"><day>7</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d29e65" ext-link-type="doi" xlink:href="10.1186/s12931-016-0491-8"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum</title><p id="Par1">Upon Publication of the original article [<xref ref-type="bibr" rid="CR1">1</xref>] several discrepancies were highlighted in the following sections; Results, Table 1, Table <xref rid="Tab1" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">3</xref>. These errors have since been acknowledged and corrected in this erratum</p><p id="Par2">
<bold>The first sentence in the subsection &#x0201c;Baseline characteristics&#x0201d; originally read:</bold> Patients&#x02019; baseline and demographic characteristics are shown in Table 1 (mITT population).</p><p id="Par3">
<bold>This should read:</bold> Patients&#x02019; baseline and demographic characteristics are shown in Table 1.</p><p id="Par4">
<bold>The header of Table 1 read:</bold> Baseline demographics (mITT population)</p><p id="Par5">
<bold>This should read as:</bold> Baseline demographics (ITT population)</p><p id="Par6">It was noticed that Table <xref rid="Tab1" ref-type="table">2</xref> contained an error. In Table <xref rid="Tab1" ref-type="table">2</xref>, data row 2, the footnote symbol &#x02018;c&#x02019; was erroneously included in the third column. The footnote symbol &#x02018;c &#x02018;should be placed in the second column in this row. The corrected Table <xref rid="Tab1" ref-type="table">2</xref> is shown below.<table-wrap id="Tab1"><label>Table 2</label><caption><p>FEV<sub>1</sub> AUC<sub>0&#x02013;12</sub> at Day 7: GFF MDI 72/9.6&#x000a0;&#x003bc;g and 36/9.6&#x000a0;&#x003bc;g comparisons (mITT population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="8">LSM treatment differences for GFF MDI in FEV<sub>1</sub> AUC<sub>0&#x02013;12</sub> at Day 7</th></tr><tr><th/><th colspan="2">GFF MDI</th><th rowspan="2">GP MDI 36&#x000a0;&#x003bc;g</th><th rowspan="2">Open-label tiotropium 18&#x000a0;&#x003bc;g</th><th colspan="2">FF MDI</th><th rowspan="2">Placebo MDI</th><th rowspan="2">Open-label FF<sup>a</sup> DPI 12&#x000a0;&#x003bc;g</th></tr><tr><th>Comparator</th><th>72/9.6&#x000a0;&#x003bc;g</th><th>36/9.6&#x000a0;&#x003bc;g</th><th>9.6&#x000a0;&#x003bc;g</th><th>7.2&#x000a0;&#x003bc;g</th></tr></thead><tbody><tr><td colspan="9">GFF MDI 72/9.6&#x000a0;&#x003bc;g</td></tr><tr><td>&#x02003;LSM<sup>b</sup> difference (SE), L 95% CI</td><td>NA</td><td>0.008 (0.0236)&#x02013;0.039, 0.054<sup>c</sup>
</td><td>0.109 (0.0250)<sup>&#x02020;</sup>0.059, 0.158</td><td>0.103 (0.0216)<sup>&#x02020;</sup>0.060, 0.145</td><td>0.116 (0.0245)<sup>&#x02020;</sup>0.068, 0.165</td><td>0.124 (0.0237)<sup>&#x02020;</sup>0.078, 0.171</td><td>0.298 (0.0261)<sup>&#x02020;</sup>0.247, 0.349</td><td>0.101 (0.0241)<sup>&#x02020;</sup>0.053, 0.148</td></tr><tr><td colspan="9">GFF MDI 36/9.6&#x000a0;&#x003bc;g</td></tr><tr><td>&#x02003;LSM<sup>b</sup> difference (SE), L 95% CI</td><td>See above</td><td>NA</td><td>0.101 (0.0245)<sup>&#x02020;</sup>0.053, 0.149</td><td>0.095 (0.0213)<sup>&#x02020;</sup>0.053, 0.137</td><td>0.109 (0.0242)<sup>&#x02020;</sup>0.061, 0.156</td><td>0.116 (0.0236)<sup>&#x02020;</sup>0.070, 0.163</td><td>0.290 (0.0261)<sup>&#x02020;</sup>0.239, 0.342</td><td>0.093 (0.0241)<sup>***</sup>0.045, 0.140</td></tr></tbody></table><table-wrap-foot><p>
<sup>***</sup>
<italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001; <sup>&#x02020;</sup>
<italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.0001</p><p>
<sup>a</sup>Foradil&#x000ae; Aerolizer&#x000ae;; <sup>b</sup>LSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid bias in treatment effect estimates; <sup>c</sup>non-inferiority comparison</p><p>CI, confidence interval; DPI, dry powder inhaler; FEV<sub>1</sub> AUC<sub>0&#x02013;12</sub>, forced expiratory volume in 1&#x000a0;s area under the curve from 0 to 12&#x000a0;h post-dose; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler; mITT, modified intent-to-treat; NA, not available; SE, standard error</p></table-wrap-foot></table-wrap>
</p><p id="Par7">It was noticed that in Fig. <xref rid="Fig1" ref-type="fig">3b</xref>, the error bar on the 4th data point (AUC<sub>inf</sub>) was incorrectly given. The error bar on the 4th data point (AUCinf) should range from 74.88, to 103.28 The corrected Fig. <xref rid="Fig1" ref-type="fig">3b</xref> is shown below.<fig id="Fig1"><label>Fig. 3</label><caption><p>Ratio of geometric LSMs and 90% CIs. (<bold>a</bold>) GFF MDI 36/9.6&#x000a0;&#x003bc;g versus GP MDI 36&#x000a0;&#x003bc;g (<bold>b</bold>) GFF MDI 36/9.6&#x000a0;&#x003bc;g versus FF MDI 9.6&#x000a0;&#x003bc;g (<bold>c</bold>) FF MDI 9.6&#x000a0;&#x003bc;g versus FF DPI (PK-mITT population). <sup>a</sup>LSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid bias in treatment effect estimates. <sup>b</sup>Foradil&#x000ae; Aerolizer&#x000ae;<sup>.</sup>AUC<sub>0&#x02013;inf</sub>, area under the curve from time 0 to infinity; AUC<sub>0&#x02013;12</sub>, area under the curve from 0 to 12&#x000a0;h post-dose; CI, confidence interval; C<sub>max</sub>, maximum observed plasma concentration; DPI, dry powder inhaler; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler; PK-mITT, pharmacokinetic modified intent-to-treat</p></caption><graphic xlink:href="12931_2017_638_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par8">These corrections do not change the conclusions of the article.</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1186/s12931-016-0491-8
</p></fn></fn-group><ref-list id="Bib1"><title>Reference</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reisner</surname><given-names>C</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Kerwin</surname><given-names>EM</given-names></name><name><surname>Fogarty</surname><given-names>C</given-names></name><name><surname>Spangenthal</surname><given-names>S</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Darken</surname><given-names>P</given-names></name><name><surname>Rose</surname><given-names>ES</given-names></name></person-group><article-title>A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel co-suspension&#x02122; delivery technology in patients with moderate-to-very severe chronic obstructive pulmonary disease</article-title><source>Respir Res</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s12931-016-0491-8</pub-id><pub-id pub-id-type="pmid">28061907</pub-id></element-citation></ref></ref-list></back></article>